Core Viewpoint - Medical technology company Medtronic has been ordered to pay $382 million in damages to Applied Medical Resources for unlawfully monopolizing the market for blood-vessel sealing surgical devices [1] Group 1: Legal and Financial Implications - The ruling highlights significant legal challenges for Medtronic in maintaining its market position [1] - The $382 million damages could impact Medtronic's financial performance and investor confidence [1] Group 2: Market Dynamics - The case underscores competitive pressures in the medical device industry, particularly in the blood-vessel sealing segment [1] - The outcome may influence future market strategies and pricing for surgical devices among competitors [1]

Core Viewpoint - Boston Scientific Corporation is experiencing strong financial performance, leading to optimistic price targets from analysts, particularly Needham, who set a target of $97, indicating a potential increase of approximately 28.44% from the current trading price of $75.52 [2][6]. Financial Performance - Boston Scientific reported fourth-quarter revenues of $5.29 billion, slightly surpassing the consensus estimate of $5.28 billion [2][6]. - The adjusted earnings per share for the fourth quarter were 80 cents, exceeding both the consensus estimate of 78 cents and the management's guidance of 77 to 79 cents [3][6]. Growth Outlook - The company forecasts net sales growth of approximately 10.5% to 11.5% in 2026 on a reported basis, and 10% to 11% organically [4]. - Expected sales for 2026 are projected to be between $22.18 billion and $22.38 billion, aligning closely with the consensus of $22.37 billion [4][6]. Market Reaction - Following the earnings announcement, BSX shares rose by 0.6% to $75.92 in pre-market trading, although the stock is currently priced at $75.45, reflecting a slight decrease of approximately 0.07% [5]. - The company's market capitalization remains robust at approximately $111.9 billion, indicating strong investor confidence [5].

Core Viewpoint - Medtronic is acquiring CathWorks for up to $585 million to enhance its heart devices portfolio with a new diagnostic tool [1] Group 1: Acquisition Details - The deal is valued at up to $585 million, indicating a significant investment by Medtronic in expanding its capabilities in the heart device market [1] - CathWorks is a privately held company, suggesting that this acquisition may provide Medtronic with innovative technologies that are not yet widely available in the market [1] Group 2: Strategic Implications - This acquisition aligns with Medtronic's strategy to bolster its offerings in the cardiovascular sector, which is a critical area of growth for the company [1] - The addition of CathWorks' diagnostic tool could potentially improve patient outcomes and enhance the overall effectiveness of heart disease management [1]

GALWAY, Ireland, Feb. 3, 2026 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it will exercise its option to acquire CathWorks, a privately held medical device company, which aims to transform how coronary artery disease (CAD) is diagnosed and treated. The intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the CathWorks FFRangio® System in the U.S., Europe and Japan, where it is commercially available. The ac ...

Core Insights - Medtronic announced three significant milestones in the U.S. aimed at expanding access and flexibility for individuals with type 1 and insulin-requiring type 2 diabetes, including Medicare access for the MiniMed™ 780G system with the Instinct sensor, FDA clearance for its use with ultra rapid-acting insulins, and clearance for use with insulin-requiring type 2 diabetes [1][2][6]. Group 1: Medicare Access - Medicare beneficiaries can now access the MiniMed™ 780G system paired with the Instinct sensor, which is small, thin, and can be worn discreetly for up to 15 days [3][5]. - This milestone enhances sensor choice for Medicare users, who also have access to the Simplera Sync™ and Guardian™ 4 sensors [3]. Group 2: FDA Clearances - The FDA has cleared the MiniMed™ 780G system for use with ultra rapid-acting insulins, such as Fiasp and Lyumjev, providing more flexibility and personalization in diabetes therapy [6]. - The system's Meal Detection™ technology allows for better management of mealtime insulin delivery, accommodating missed or delayed doses [6]. Group 3: Benefits of the MiniMed™ 780G System - The MiniMed™ 780G system automates insulin delivery every five minutes, which helps maintain stable glucose control and reduces the burden of daily decision-making for users [4][9]. - The integration of the Instinct sensor with the MiniMed™ 780G system is expected to improve the daily management experience for individuals with type 2 diabetes [10].

Company Performance - Medtronic's stock increased by 1.94% to $102.96, outperforming the S&P 500, which fell by 0.43% [1] - Over the past month, Medtronic shares gained 5.14%, while the Medical sector declined by 2.36% and the S&P 500 rose by 0.89% [1] Upcoming Earnings - Medtronic is set to release its earnings report on February 17, 2026, with an expected EPS of $1.33, reflecting a 4.32% decrease from the same quarter last year [2] - Revenue is anticipated to be $8.9 billion, indicating a 7.29% increase compared to the previous year [2] Annual Estimates - For the annual period, Zacks Consensus Estimates project earnings of $5.64 per share and revenue of $36.04 billion, representing increases of 2.73% and 7.46%, respectively, from last year [3] Analyst Sentiment - Recent changes to analyst estimates for Medtronic are crucial, as positive revisions indicate optimism about the company's business and profitability [3][4] - The Zacks Rank system, which evaluates estimate changes, currently ranks Medtronic at 4 (Sell) [5] Valuation Metrics - Medtronic has a Forward P/E ratio of 17.9, which is lower than the industry average of 19.03 [6] - The company's PEG ratio stands at 2.66, compared to the industry average PEG ratio of 1.69 [6] Industry Context - The Medical - Products industry, which includes Medtronic, has a Zacks Industry Rank of 158, placing it in the bottom 36% of over 250 industries [7] - The top 50% rated industries tend to outperform the bottom half by a factor of 2 to 1 [7]

Company Overview - Medtronic is a leading global healthcare solutions company operating in the medical technology sector, developing and manufacturing medical devices and therapies for various health conditions [1] - The company competes with major players in the healthcare industry, including Johnson & Johnson and Boston Scientific [1] Stock Performance - Medtronic's stock is currently priced at $101, reflecting a slight increase of 0.21, or 0.21%, from the previous trading session [2] - The stock has fluctuated between a low of $99.69 and a high of $101.59 today, with a yearly high of $106.33 and a low of $79.55 [2] - The market capitalization of Medtronic is approximately $129.5 billion, with a trading volume of 7.67 million shares today [2] Analyst Coverage - CICC initiated coverage on Medtronic with a bullish view, assigning it an "Outperform" grade, indicating a positive outlook on the company's future [5] - The current stock price of $101 shows investor confidence, aligning with the positive outlook from CICC [5] Investment Strategy - Eaton Vance Worldwide Health Sciences Fund has reduced its stake in Novo Nordisk AS by 49.25%, indicating a strategic shift in its investment approach [3] - The fund targets companies involved in healthcare product and service innovation, driven by growth potential associated with aging demographics and increasing global incomes [3] - The fund's strategy emphasizes acquiring reasonably priced stocks with long-term growth potential, which aligns with the bullish view on Medtronic [4]

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Medical device mergers and acquisitions accelerated in the second half of 2025, propelled by several large deal announcements, according to a report released this month by Bain & Company. Medtech M&A brought in a total value of about $80 billion through Nov. 30, 2025, surpassing the previous three years. Much of the activity took place in the second half of the ye ...

New York City Mayor Zohran Mamdani faces his first major test as a massive snowstorm hits the city. Partnership for New York City President and CEO Steven Fulop, in his first TV interview since taking the helm, discusses the outlook for business in New York under Mamdani’s leadership. Then, after 60 executives of Minnesota-based companies co-signed a letter calling for calm in Minneapolis, former chairman and CEO of Minnesota-based Medtronic Bill George weighs in the corporate response to the fatal shooting ...

As filed with the Securities and Exchange Commission on January 23, 2026. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MiniMed Group, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 3841 33-3985981 (I.R.S. Employer Identification Number) 18000 Devonshire St. N ...